Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This trial is conducted in Europe and Asia. The aim of this trial is to compare basal bolus treatment with insulin aspart and insulin NPH to biphasic insulin aspart treatment on blood glucose control in type 2 diabetes.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Type 2 diabetes
Currently treated with human insulin or insulin analogues for at least 3 months, with or without combination with OADs
HbA1c between 8.0-10.5%
Body mass index (BMI) below 35.0 kg/m2
Able and willing to perform self-monitoring of blood glucose
Total daily insulin dose of 1.80 IU/kg or more
Known or suspected allergy to trial product or related products
Pregnancy, breast-feeding, the intention to become pregnant or judged not to be using adequate contraceptive measures